查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1683388

全球奈米技术药物传输设备市场 - 2025 至 2033 年

Global Nanotechnology-Enabled Drug Delivery Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 159 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球奈米技术药物输送设备市场规模达到 542.2 亿美元，预计到 2033 年将达到 1,791.2 亿美元，在 2025-2033 年预测期内的复合年增长率为 12.6%。

奈米技术的药物传输装置是利用奈米技术提高治疗剂的功效、精确度和安全性的先进系统。这些装置使用奈米粒子、脂质体、树枝状聚合物和聚合物胶束等奈米级材料来增强药物溶解度、生物利用度和向特定组织或细胞的靶向传递。这些系统最大限度地减少了副作用，增强了治疗效果，并实现了个人化的治疗方法，特别是在肿瘤学、神经病学和传染病治疗方面。

市场动态：

驱动因素与约束因素

提高药物生物利用度和标靶输送

由于奈米技术能够提高药物生物利用度和标靶输送，全球药物输送装置市场正在不断扩大。这些系统透过将药物输送到特定组织或患病细胞来增强治疗效果，并最大限度地减少副作用。它们在肿瘤学、神经病学和心血管疾病中特别有用，因为它们可以提高溶解度、延长循环时间并允许控制药物释放。这些创新也促进了药物跨越生物屏障的运输，这对于治疗复杂疾病至关重要。

可扩展性和製造复杂性有限

全球奈米技术药物传输设备市场面临重大挑战，因为大规模製造的复杂性，包括精密工程、专门设施和严格的品质控制措施。奈米颗粒尺寸、稳定性和药物负载效率的变化会影响产品的一致性，进而导致监管受挫。维护先进製造基础设施和确保批次间一致性的高成本进一步限制了市场扩张，限制了奈米技术在药物传输中的广泛应用。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第 3 章：动态

  • 影响因素
    • 驱动程式
      • 提高药物生物利用度和标靶输送
      • 奈米科技的进步
    • 限制
      • 可扩展性和製造复杂性有限
      • 开发和製造成本高
    • 机会
      • 与人工智慧和智慧药物传输系统的整合
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 5 章：依产品类型

  • 奈米晶体
  • 奈米粒子
  • 脂质体
  • 胶束
  • 奈米管
  • 其他的

第 6 章：按应用

  • 神经病学
  • 肿瘤学
  • 心血管/生理学
  • 抗发炎/免疫学
  • 抗感染
  • 其他的

第 7 章：按最终用户

  • 医院和诊所
  • 研究机构和实验室
  • 製药和生物技术公司
  • 其他的

第 8 章：按区域市场分析与成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Merck & Co., Inc
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 主要进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Pfizer Inc.
  • Novartis AG
  • Sanofi SA
  • Gilead Sciences, Inc.
  • GSK

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD9330

The global nanotechnology-enabled drug delivery devices market reached US$ 54.22 billion in 2024 and is expected to reach US$ 179.12 billion by 2033, growing at a CAGR of 12.6% during the forecast period 2025-2033.

Nanotechnology-enabled drug delivery devices are advanced systems that use nanotechnology to improve the efficacy, precision, and safety of therapeutic agents. These devices use nanoscale materials like nanoparticles, liposomes, dendrimers, and polymeric micelles to enhance drug solubility, bioavailability, and targeted delivery to specific tissues or cells. These systems minimize side effects, enhance therapeutic outcomes, and enable personalized treatment approaches, particularly in oncology, neurology, and infectious disease treatments.

Market Dynamics: Drivers & Restraints

Enhanced Drug Bioavailability and Targeted Delivery

The global market for nanotechnology-enabled drug delivery devices is expanding due to its ability to improve drug bioavailability and targeted delivery. These systems enhance therapeutic effectiveness by delivering drugs to specific tissues or diseased cells, minimizing side effects. They are particularly useful in oncology, neurology, and cardiovascular diseases, as they improve solubility, prolong circulation time, and allow controlled drug release. These innovations also facilitate drug transport across biological barriers, making them crucial for treating complex conditions.

Limited Scalability and Manufacturing Complexities

The global nanotechnology-enabled drug delivery devices market faces significant challenges due to the complexities of large-scale manufacturing, including precise engineering, specialized facilities, and strict quality control measures. Variability in nanoparticle size, stability, and drug-loading efficiency can impact product consistency, leading to regulatory setbacks. High costs associated with maintaining advanced manufacturing infrastructure and ensuring batch-to-batch uniformity further restrict market expansion, limiting the widespread adoption of nanotechnology in drug delivery.

Segment Analysis

The global nanotechnology-enabled drug delivery devices market is segmented based on product type, application, end-user and region.

Product Type:

The nanocrystals from product type segment is expected to dominate the nanotechnology-enabled drug delivery devices market with the highest market share

Nanocrystals are a key component in the global drug delivery device market, enhancing the solubility and bioavailability of water-soluble drugs. These ultra-small particles improve drug dissolution rates, leading to faster absorption and increased therapeutic efficacy. They enable controlled, targeted drug release, reducing dosage frequency and side effects. Their applications are particularly significant in oncology, neurology, and cardiovascular treatments. Nanocrystals can be administered via oral, injectable, and topical formulations, expanding their potential across multiple therapeutic areas.

Geographical Analysis

North America is expected to hold a significant position in the Nanotechnology-Enabled Drug Delivery Devices market with the highest market share

North America dominates the global nanotechnology-enabled drug delivery devices market due to strong research, a well-established pharmaceutical industry, and advanced healthcare infrastructure. Major pharmaceutical and biotechnology companies invest in nanotechnology-based solutions. The rising prevalence of chronic diseases like cancer, neurological disorders, and cardiovascular conditions drives demand for innovative drug delivery systems. Collaborations between research institutions and pharmaceutical companies drive innovation, positioning North America as a dominant player.

For instance, according to the Centers for Disease Control and Prevention 6 in 10 Americans have at least one chronic disease, with 4 in 10 having two or more. Preventable chronic diseases are often caused by risky behaviors like smoking, poor nutrition, physical inactivity, and excessive alcohol use.

Hence, North America's increasing chronic disease prevalence drives demand for advanced drug delivery solutions, promoting nanotechnology-enabled devices for treatment efficiency, side effects reduction, and improved patient compliance, boosting market growth.

Competitive Landscape

The major global players in the nanotechnology-enabled drug delivery devices market include Merck & Co., Inc, Pfizer Inc, Novartis AG, Sanofi S.A., Gilead Sciences, Inc, and GSK among others.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nanotechnology-enabled drug delivery devices market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Enhanced Drug Bioavailability and Targeted Delivery
      • 3.1.1.2. Advancements in Nanotechnology
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Scalability and Manufacturing Complexities
      • 3.1.2.2. High Development and Manufacturing Costs
    • 3.1.3. Opportunity
      • 3.1.3.1. Integration with AI and Smart Drug Delivery Systems
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Nanocrystals*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Nanoparticles
  • 5.4. Liposomes
  • 5.5. Micelles
  • 5.6. Nanotubes
  • 5.7. Others

6. By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Neurology*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Oncology
  • 6.4. Cardiovascular/Physiology
  • 6.5. Anti-inflammatory/Immunology
  • 6.6. Anti-infective
  • 6.7. Others

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals and Clinics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Research Institutes and Laboratories
  • 7.4. Pharmaceutical and Biotechnology Companies
  • 7.5. Others

8. By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Merck & Co., Inc*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Pfizer Inc.
  • 10.3. Novartis AG
  • 10.4. Sanofi S.A.
  • 10.5. Gilead Sciences, Inc.
  • 10.6. GSK

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us